DataMeds AI files draft information statement
MEDS•DataMeds AI shareholders authorized the issuance of shares upon conversion of a $1.36 million note held by Axe Compute. The note converts at an initial price of $1 per share, with accrued interest potentially adding shares and qualifying lower-priced issuances reducing the conversion price.
1. Note conversion terms
The note was issued on September 11, 2026, as consideration for the Helomics acquisition and carries 7% annual simple interest. Its principal converts into 1,363,672 shares at the initial $1 conversion price; unpaid accrued interest may generate additional shares. Conversion becomes automatic when shareholder approval takes effect, and qualifying lower-priced share issuances would reduce the conversion price, increasing potential dilution.




